3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
17
Tumor-Agnostic
7
Gynecologic
4
Head & Neck
2
Endocrine
2
Thoracic
1
Genitourinary
1
Conditions
Multiple Endocrine Neoplasia Type 1
5
Breast Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Neoplasms by Site
1
Hyperglycemia
1
Breast Diseases
1
Interventions
Everolimus
6
Sunitinib
4
Octreotide
4
Leucovorin
4
dabrafenib
3
Fluorouracil
3
3-Iodobenzylguanidine
3
trametinib
2
selpercatinib
2
lutetium Lu 177 dotatate
2
avelumab
2
alectinib
2
PM 01183
2
Oxaliplatin
2
Irinotecan
2
Fulvestrant
2
Drug Therapy
2
Doxorubicin
2
Cisplatin
2
trifluridine tipiracil drug combination
1
tipifarnib
1
telotristat ethyl
1
surufatinib
1
somapacitan
1
ribociclib
1
repotrectinib
1
pralsetinib
1
pentetreotide
1
pegfilgrastim
1
pasireotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Fulvestrant
×
Endocrine
×
Clear all
NCT02437318
2025-02-13
SOLAR-1
Novartis
Phase 3
Completed
572 enrolled
22 charts
1 FDA
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA